7 results
Primary: to compare the treatment effect of ranibizumab PRN (visual acuity loss and/or SD-OCT disease activity guided retreatment) versus aflibercept bimonthly regimen on central retinal thickness stability as measured by mean fluctuations between…
Primary ObjectiveTo investigate whether half-dose PDT treatment leads to a higher percentage of chronic CSC patients with subretinal fluid on OCT achieving an absence of this subretinal fluid on OCT as compared to HSML treatment.Secondary…
Primary objectives:- To investigate the long-term outcome after successful treatment (no subretinal fluid on OCT) in the PLACE trial.- To investigate whether a cross-over treatment of half-dose PDT to HSML in cCSC patients who either did not respond…
The objective of this study is to observe the anatomical and functional outcomes of ocriplasmin over a 6-month follow-up period.
To examine features of treatment response on optical coherence tomography in patients who were switched to aflibercept after non-response to previous intravitreal anti-VEGF treatment.
Evaluating the long term safety and tolerability of ranibizumab treatment of AMD patients.
Primary Objective: to investigate whether half-dose PDT treatment leads to a higher percentage of cCSC patients with SRF on OCT at baseline, achieving an absence of this SRF on OCT as compared to eplerenone treatment.Secondary Objectives: to…